BACKGROUND: Schizophrenia (SZ) is characterized by a broad global cognitive impairment that precedes the onset of the disease. By contrast, some studies suggest that premorbid deficits are absent, or even reversed, in bipolar disorder (BD). However, studies have shown impairments in cognitive functioning after the illness onset in both disorders. The aim of this study was to systematically review and meta-analyze those studies that compared premorbid and/or post-onset global cognitive function between SZ and BD. METHOD: We searched Medline (PubMed), EMBASE and PsycINFO for studies where information on cognitive functioning was collected in both SZ and BD within the same study or using the same methods. RESULTS: Compared to healthy comparison groups, SZ patients showed a significant premorbid cognitive impairment [standardized mean difference (SMD) -0.597, 95% confidence interval (CI) -0.707 to -0.487, p < 0.0001] and a large post-onset impairment (SMD -1.369, 95% CI -1.578 to -1.160, p < 0.0001). We found small significant deficits in premorbid intellectual function in the BD group when this was assessed retrospectively (-0.147, 95% CI -0.238 to -0.056, p = 0.001) but not prospectively (-0.029, 95% CI -0.199 to + 0.142, p = 0.744), and moderate cognitive impairment after onset (SMD -0.623, 95% CI -0.717 to -0.529, p < 0.0001). CONCLUSIONS: SZ is characterized by significant deficits in premorbid intellectual function but the evidence regarding premorbid function in BD is equivocal. After illness onset, patients with both disorders seem to suffer a further decline in cognitive function but the magnitude of the impairment remains greater in SZ than in BD.
BACKGROUND:Schizophrenia (SZ) is characterized by a broad global cognitive impairment that precedes the onset of the disease. By contrast, some studies suggest that premorbid deficits are absent, or even reversed, in bipolar disorder (BD). However, studies have shown impairments in cognitive functioning after the illness onset in both disorders. The aim of this study was to systematically review and meta-analyze those studies that compared premorbid and/or post-onset global cognitive function between SZ and BD. METHOD: We searched Medline (PubMed), EMBASE and PsycINFO for studies where information on cognitive functioning was collected in both SZ and BD within the same study or using the same methods. RESULTS: Compared to healthy comparison groups, SZ patients showed a significant premorbid cognitive impairment [standardized mean difference (SMD) -0.597, 95% confidence interval (CI) -0.707 to -0.487, p < 0.0001] and a large post-onset impairment (SMD -1.369, 95% CI -1.578 to -1.160, p < 0.0001). We found small significant deficits in premorbid intellectual function in the BD group when this was assessed retrospectively (-0.147, 95% CI -0.238 to -0.056, p = 0.001) but not prospectively (-0.029, 95% CI -0.199 to + 0.142, p = 0.744), and moderate cognitive impairment after onset (SMD -0.623, 95% CI -0.717 to -0.529, p < 0.0001). CONCLUSIONS: SZ is characterized by significant deficits in premorbid intellectual function but the evidence regarding premorbid function in BD is equivocal. After illness onset, patients with both disorders seem to suffer a further decline in cognitive function but the magnitude of the impairment remains greater in SZ than in BD.
Entities:
Keywords:
Bipolar disorder; cognitive function; first episode; intelligence; meta-analysis; pre- and post-onset; schizophrenia; systematic review
Authors: Brandee Feola; Kristan Armstrong; Neil D Woodward; Stephan Heckers; Jennifer Urbano Blackford Journal: Psychiatry Res Date: 2019-03-11 Impact factor: 3.222
Authors: Tomas Hajek; Katja Franke; Marian Kolenic; Jana Capkova; Martin Matejka; Lukas Propper; Rudolf Uher; Pavla Stopkova; Tomas Novak; Tomas Paus; Miloslav Kopecek; Filip Spaniel; Martin Alda Journal: Schizophr Bull Date: 2019-01-01 Impact factor: 9.306
Authors: A Vreeker; M P M Boks; L Abramovic; S Verkooijen; A H van Bergen; M H J Hillegers; A T Spijker; E Hoencamp; E J Regeer; R F Riemersma-Van der Lek; A W M M Stevens; P F J Schulte; R Vonk; R Hoekstra; N J M van Beveren; R W Kupka; R M Brouwer; C E Bearden; J H MacCabe; R A Ophoff Journal: Psychol Med Date: 2015-12-01 Impact factor: 7.723
Authors: Annabel Vreeker; Lucija Abramovic; Marco P M Boks; Sanne Verkooijen; Annet H van Bergen; Roel A Ophoff; René S Kahn; Neeltje E M van Haren Journal: J Affect Disord Date: 2017-07-06 Impact factor: 4.839
Authors: Gisela Sugranyes; Elena de la Serna; Roger Borras; Vanessa Sanchez-Gistau; Jose C Pariente; Soledad Romero; Inmaculada Baeza; Covadonga M Díaz-Caneja; Elisa Rodriguez-Toscano; Carmen Moreno; Miguel Bernardo; Dolores Moreno; Eduard Vieta; Josefina Castro-Fornieles Journal: Schizophr Bull Date: 2017-10-21 Impact factor: 9.306
Authors: Lucija Abramovic; Marco P M Boks; Annabel Vreeker; Sanne Verkooijen; Annet H van Bergen; Roel A Ophoff; René S Kahn; Neeltje E M van Haren Journal: Eur Neuropsychopharmacol Date: 2018-05-18 Impact factor: 4.600